Vonoprazan–minocycline dual therapy as a first-line treatment of Helicobacter pylori infection compared with empirical bismuth-containing quadruple therapy

医学 米诺环素 幽门螺杆菌 幽门螺杆菌感染 铋 螺杆菌 内科学 胃肠病学 抗生素 微生物学 生物 冶金 材料科学
作者
Meng Li,Xiaolei Wang,Xinhong Dong,Guigen Teng,Yun Dai,Weihong Wang
出处
期刊:Therapeutic Advances in Gastroenterology [SAGE Publishing]
卷期号:18: 17562848251366156-17562848251366156 被引量:9
标识
DOI:10.1177/17562848251366156
摘要

Background: Increasing antibiotic resistance compromises therapeutic options for Helicobacter pylori ( H. pylori ) infection, especially in penicillin-allergic individuals. Objectives: This trial aimed to assess the efficacy and safety of 14-day vonoprazan–minocycline (VM) dual therapy against bismuth-containing quadruple therapy (B-quadruple therapy), as initial treatment for H. pylori infection. Design: This study was a single-center, open-label, and non-inferiority randomized controlled trial. Methods: In this study, 240 individuals with H. pylori infection who have not received therapy were randomly assigned 1:1 to either the VM dual therapy group (vonoprazan 20 mg plus minocycline 100 mg, administered twice daily) or the B-quadruple therapy group (rabeprazole 10 mg, amoxicillin 1000 mg, clarithromycin 500 mg, and bismuth potassium citrate 220 mg, all administered twice daily). The primary outcome was to evaluate the non-inferiority of eradication rates between the two groups. Secondary outcomes included assessments of AEs and compliance. Results: The eradication rates of VM dual group and B-quadruple therapy group were 87.5% and 88.3%, respectively, by intention-to-treat (ITT) analysis; 92.1% and 94.6% by modified ITT (mITT) analysis; and 92.0% and 95.5% by per-protocol (PP) analysis. The eradication rates of the VM group were non-inferior to those of the B-quadruple therapy group in ITT, mITT, and PP analyses (one-sided p -values were 0.02, 0.01, and 0.02). The incidence of AEs was higher in the B-quadruple therapy group (28.3%) than in the VM group (16.7%, p = 0.03). Good compliance was achieved in both groups ( p = 0.60). Conclusion: The VM dual therapy was not inferior to the B-quadruple therapy in the initial treatment of H. pylori infection, and the incidence of AEs was lower compared to B-quadruple therapy. Trial registration: This trial was registered on the Chinese Clinical Trial Registry with the registration number ChiCTR2400081461.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zm发布了新的文献求助10
刚刚
邵简完成签到,获得积分10
1秒前
虾球完成签到,获得积分10
1秒前
广州队完成签到,获得积分0
1秒前
完美平文完成签到,获得积分10
1秒前
yang完成签到,获得积分10
1秒前
深情安青的应助被小美爱科研采纳,获得10
1秒前
Zzwde完成签到,获得积分10
1秒前
十六月夜完成签到,获得积分0
1秒前
shmily完成签到,获得积分10
2秒前
专注的玉米完成签到,获得积分10
3秒前
希望天下0贩的0的应助被hzy采纳,获得10
3秒前
3秒前
3秒前
饱满含玉完成签到,获得积分10
3秒前
3秒前
查不到我就吃饭完成签到 ,获得积分10
3秒前
3秒前
火星上秋烟完成签到,获得积分10
3秒前
初学者发布了新的文献求助10
3秒前
冷月完成签到,获得积分10
3秒前
YooPhD完成签到 ,获得积分10
4秒前
细心的山槐完成签到,获得积分10
4秒前
ROOT完成签到,获得积分10
4秒前
自然思烟完成签到,获得积分10
4秒前
焦糖咸鱼发布了新的文献求助10
4秒前
奋斗的誉完成签到,获得积分10
4秒前
asdmwhx完成签到,获得积分10
5秒前
5秒前
张JN发布了新的文献求助10
5秒前
5秒前
姜小鹿完成签到,获得积分10
5秒前
调皮惜天完成签到,获得积分10
5秒前
晨霭微凉完成签到,获得积分10
6秒前
ljy2015完成签到,获得积分10
6秒前
嘻嘻完成签到,获得积分10
6秒前
zhanng完成签到 ,获得积分10
6秒前
阳光致远完成签到,获得积分10
6秒前
那花那朵06完成签到,获得积分10
6秒前
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology)求助 1000
Encyclopedia of Modern Artificial Intelligence 1000
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8152226
求助须知:如何正确求助?哪些是违规求助? 9549007
关于积分的说明 21689901
捐赠科研通 7740494
什么是DOI,文献DOI怎么找? 3425145
关于科研通互助平台的介绍 2550358
邀请新用户注册赠送积分活动 2468652